Momenta Pharmaceuticals, Inc. (MNTA)

[biopearl]

Fellow board members, 13 is getting close to my entry point of about 10 years ago and I continue to hold. Wonder if anyone thinks the basic premise of being able to make exact copies of biologics (MNTAs raison detre), that presumably would be attractive to the FDA has been challenged to the point of invalidity since clearly other competitors now presumably have workarounds that perhaps initially some including myself thought would be unique to MNTA. It appears to be a world driven by legal hurdles even more that biologic ones. Once MNTA Copax 40 is approved clearly some additional and substantial income should be derived and the decline should reverse. Not what we thought but still not hay. Is anyone of the mind to continue to hold? Clearly Mylan looks to MNTA for their future biosimilar program but this and the antibody program both of which may prove successful have a long timeline. Thanks bp